<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147331</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Spanish adaptation of Beers criteria</dc:title>
<dc:description xml:lang="en">Background. The Beers criteria, which were drawn up in the USA and updated in 2012, were developed to detect potentially inappropriate prescriptions in older adults. Since there are significant differences between the Spanish and North American drug catalogues, our aim was to produce a Spanish adaptation of the criteria. Patients and methods. A comparison of the drugs mentioned in the Beers list with the 2012 Spanish Drugs Catalogue identified those active substances that were on the list in the USA but not commercially available in Spain. We also searched for Spanish drugs that were similar to those listed in the criteria. If these drugs were available in the USA, it was assumed that they had been evaluated by the Beers authors. On the other hand, if similar active substances were not available in the USA, they were evaluated by reference to three information sources: articles reviewed by the American Geriatrics Society in support of the Beers criteria, the product characteristics and information leaflets, and the European STOPP/START, NORGEP and PRISCUS criteria. Results. Of the 199 active substances listed in the Beers criteria, 54 (27.0%) were not commercially available in Spain, but 50 new active substances could be included. These figures differed when &#147;Direct Criteria&#148; were considered: 47 (34.3%) active substances were not commercially available in Spain and 40 new ones could be included in the Beers list. As regards &#147;Disease Dependent Criteria&#148; the figures were 33 (21.3%) and 48, respectively. Conclusions. A great number of drugs on the Beers list were not commercially available in Spain, and we added many active substances not included in the original version. This study is thus an adaptation of the Beers Criteria to the Spanish health care scenario (AU)</dc:description>
<dc:creator>Rausell Rausell, VJ</dc:creator>
<dc:creator>Aranda García, A</dc:creator>
<dc:creator>Tobaruela Soto, M</dc:creator>
<dc:creator>Gascón Cánovas, JJ</dc:creator>
<dc:creator>Pastor Cano, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento. Los Criterios de Beers, de procedencia estadounidense y actualizados en 2012, son una herramienta asesora en la prescripción en pacientes ancianos. Dadas las diferencias entre nuestro catálogo de medicamentos y el norteamericano, el objetivo del estudio fue obtener una adaptación española de dichos criterios. Material y método. La comparación de los Criterios de Beers con el catálogo español de medicamentos de 2012 permitió detectar los principios activos, presentes en los criterios, no comercializados en España. Además se buscaron medicamentos comercializados en España similares a los presentes en los criterios. Se asume que los medicamentos comercializados en Estados Unidos ya fueron evaluados en la elaboración de los Beers. Así, sobre los medicamentos similares, disponibles en España y no en Estados Unidos, se realizó una evaluación de acuerdo a 3 tipos de fuentes: los artículos presentados por la American Geriatrics Society para avalar la evidencia de los Beers; las fichas técnicas y prospectos; y los criterios europeos STOPP/START, NORGEP y PRISCUS. Resultados. De los 199 principios activos presentes en los criterios Beers, se detectaron 54 (27,0%) no comercializados en España. Además se incorporaron 50 principios activos. Entre el grupo de los &#147;Criterios Directos&#148; se detectaron 47 (34,3%) no disponibles y 40 posibles inclusiones, y en el grupo de los &#147;Criterios Dependientes de Enfermedad&#148; 33 (21,3%) y 48 respectivamente. Conclusiones. Se ha detectado una importante presencia de medicamentos no comercializados en España, así como un elevado número de principios activos no incluidos en la versión original. Este trabajo facilita una adaptación de los Criterios de Beers a los profesionales de nuestro entorno (AU)</dc:description>
<dc:source>An Sist Sanit Navar;38(3): 375-385, sept.-dic. 2015. tab, ilus</dc:source>
<dc:identifier>ibc-147331</dc:identifier>
<dc:title xml:lang="es">Adaptación española de los criterios Beers</dc:title>
<dc:subject>^d54219^s22024</dc:subject>
<dc:subject>^d7152^s22011</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d54219^s22020</dc:subject>
<dc:subject>^d7152^s22012</dc:subject>
<dc:subject>^d23106^s22044</dc:subject>
<dc:subject>^d7152^s22053</dc:subject>
<dc:subject>^d54219^s22056</dc:subject>
<dc:subject>^d54219^s22011</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23106^s22048</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d7152^s22024</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d13411^s22028</dc:subject>
<dc:type>article</dc:type>
<dc:date>201512</dc:date>
</metadata>
</record>
</ibecs-document>
